NASDAQ:EYPT Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $10.00 -0.07 (-0.70%) As of 12:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eyepoint Pharmaceuticals Stock (NASDAQ:EYPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get EYPT alerts:Sign Up Key Stats Today's Range$9.68▼$10.3750-Day Range$7.21▼$11.0652-Week Range$3.91▼$13.98Volume167,595 shsAverage Volume803,540 shsMarket Capitalization$688.11 millionP/E RatioN/ADividend YieldN/APrice Target$25.78Consensus RatingBuy Company Overview EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Read More Eyepoint Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreEYPT MarketRank™: Eyepoint Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat, and ranked 728th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEyepoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyepoint Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Eyepoint Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Eyepoint Pharmaceuticals are expected to decrease in the coming year, from ($2.13) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyepoint Pharmaceuticals is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyepoint Pharmaceuticals is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyepoint Pharmaceuticals has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.77% of the outstanding shares of Eyepoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Eyepoint Pharmaceuticals has recently decreased by 3.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyepoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyepoint Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.77% of the outstanding shares of Eyepoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Eyepoint Pharmaceuticals has recently decreased by 3.03%, indicating that investor sentiment is improving. News and Social Media1.7 / 5News Sentiment0.03 News SentimentEyepoint Pharmaceuticals has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Eyepoint Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eyepoint Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.46% of the stock of Eyepoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eyepoint Pharmaceuticals' insider trading history. Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Stock News HeadlinesEyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down After Earnings MissAugust 8 at 2:45 AM | americanbankingnews.comEyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To ExpectAugust 7 at 7:45 AM | finance.yahoo.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...August 8 at 2:00 AM | InvestorPlace (Ad)EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call TranscriptAugust 6 at 4:22 PM | seekingalpha.comEyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 6 at 7:30 AM | globenewswire.comEyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate DevelopmentsAugust 6 at 7:00 AM | globenewswire.comEyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $25.67 Average Price Target from AnalystsAugust 3, 2025 | americanbankingnews.comEyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | globenewswire.comSee More Headlines EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? Eyepoint Pharmaceuticals' stock was trading at $7.45 at the beginning of the year. Since then, EYPT stock has increased by 32.7% and is now trading at $9.8890. How were Eyepoint Pharmaceuticals' earnings last quarter? Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.18. The business had revenue of $5.33 million for the quarter, compared to analyst estimates of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative trailing twelve-month return on equity of 61.64%. Read the conference call transcript. When did Eyepoint Pharmaceuticals' stock split? Eyepoint Pharmaceuticals shares reverse split on the morning of Wednesday, December 9th 2020.The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Eyepoint Pharmaceuticals' major shareholders? Eyepoint Pharmaceuticals' top institutional shareholders include Aberdeen Group plc (1.50%), Simplify Asset Management Inc. (0.12%), Woodstock Corp (0.10%) and Levin Capital Strategies L.P. (0.03%). Insiders that own company stock include Ew Healthcare Partners, LP, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine and David R Guyer. View institutional ownership trends. How do I buy shares of Eyepoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eyepoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyepoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings8/06/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:EYPT CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees120Year Founded1987Price Target and Rating Average Price Target for Eyepoint Pharmaceuticals$25.78 High Price Target$33.00 Low Price Target$15.00 Potential Upside/Downside+158.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.87 million Net Margins-337.93% Pretax Margin-261.75% Return on Equity-61.64% Return on Assets-48.63% Debt Debt-to-Equity RatioN/A Current Ratio7.85 Quick Ratio7.79 Sales & Book Value Annual Sales$51.90 million Price / Sales13.23 Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book2.02Miscellaneous Outstanding Shares68,811,000Free Float65,742,000Market Cap$686.39 million OptionableOptionable Beta1.73 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:EYPT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.